2023³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2023-03-17±³À°ÀÏÀÚ : 2023-03-17
±³À°Àå¼Ò : ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3
±³À°ÁÖÁ¦ :
2023³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú
Âü¼®¿¹»óÀοø : 120¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í »çÀüµî·Ï ȸ¿ø: 50,000¿ø/ ºñȸ¿ø 70,000¿ø ÇöÀåµî·Ï ȸ¿ø: 60,000¿ø/ ºñȸ¿ø 80,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 13:00~13:20 Differential effector cells of CD4 versus CD8 cells during ICI treatment À̽¿ì(Æ÷Ç×°ø°ú´ëÇб³)
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 13:20~13:40 The role of ICI beyond PD-(L)1 axis (CTLA-4, TIGIT, 41BB, et al.) ¹Ú¼¼ÈÆ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 13:40~14:00 Novel class of chemo-immunotherapeutic: antibody-drug conjugate ±è¹Ì¼Ò(¼¿ï´ëº´¿ø)
Åä·Ð 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 14:00~14:10 Q&A ()
ÈÞ½Ä 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 14:10~14:30 Coffo ee break ()
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 14:30~14:50 The promising role of neoadjuvant chemo-immunotherapy ¹ÚÁöÇö(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 14:50~15:10 Should resectability be re-defined in stage III? ÀÌ⿵(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 15:10~15:30 Post-neoadjuvant biomarkers to predict the patient ±èÅÂÁ¤(¿©Àǵµ¼º¸ðº´¿ø)
Åä·Ð 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 15:30~15:40 Q&A ()
ÈÞ½Ä 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 15:40~16:00 Coffo ee break ()
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 16:00~16:20 Different TIME of ICI in ALK, ROS1, BRAF, RET, MET-altered NSCLC À±½Å±³(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 16:20~16:40 Different immunotherapy strategy according to subtypes of SCLC ÃÖÀ±¶ó(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 03-17 ¿ë»êµå·¡°ï½ÃƼ 3Ãþ Grand Ballroom Hanra 2+3 16:40~17:00 Application of microbiome therapeutics to improved TIME ±èÇѳª(»ï¼ºÀ¶ÇÕÀÇ°úÇпø)